European Archives - Page 239 of 1391 - European Medical Journal

NICE Turns Down Breakthrough Drugs for Patients with Alzheimer’s

Despite the setback, hope remains, with 138 dementia drugs currently in trials, experts say more effective, safer options may soon emerge.

25 Jun 2025

Why Are You Still Avoiding PD in Older Adults? An Interactive Case Study

For elderly patients, survival duration between hemodialysis and peritoneal dialysis, even when statistically significant, is usually in…

From Bench to Bedside and Back: An Interview with Joshua Richter

Joshua Richter – Associate Professor, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA. What initially…

Weight Loss Reduces Inflammation in Metabolic Liver Disease

Discover a study that found that individuals with higher baseline IL-1β levels experienced greater improvements in liver health following weight loss.

ERA 2025 Interview: Rainer Oberbauer

I’ve been in the field for almost 30 years now. I started by chance after my postdoctoral training. I became interested in kidney…

EAN 2025: Blood Biomarker sNfL Predicts MS Relapses Up to a Year in Advance

Blood biomarker sNfL predicts MS relapses up to a year in advance, offering new hope for earlier intervention.

Illustration of a doctor talking to a patient at a desk

New survey takes patient pulse on AI in healthcare

The survey found that, while 57% of patients support the use of AI in the examination room, they are less enthusiastic about diagnostics.

24 Jun 2025

Cardiovascular Risk and ADT in Prostate Cancer

This infographic is sponsored by Accord Healthcare and it’s intended for Health Care Professionals only

Spike in Hepatitis A Cases Hits Vulnerable Communities in Central Europe

Europe faces a sharp rise in hepatitis A cases, with over 2,000 infections in 2025. Vulnerable groups are most affected as ECDC urges vaccination and sanitation efforts.

Pfizer’s Richard Maughan on the future of access in the UK

Richard Maughan, Senior Director and Head of UK Policy and Public Affairs, Pfizer, explores how the UK is shaping access to medicine.